유방암 치료를 위한 분자표적 = Molecular Targets for Treatment of Breast Cance

다국어 초록 (Multilingual Abstract)

Advances in molecular biology have made it possible to understand the tumor biology of breast cancer at the molecular level and have revealed molecular targets for the therapy of breast cancer. Nowadays, targeting agents are used
as mono-therapy or as combined therapy with other anticancer drugs for the treatment of breast cancer. Much more efforts is also being made in the development of better therapeutic agents targeting molecules having an important role in tumor biology. In this article, promising molecules for targeted
therapy are reviewed for their roles in the pathophysiology and the treatment of breast cancer. We also introduce and summarize new preclinical agents, developed or on developing, with preliminary results from clinical trials. Given
the progress currently being made, targeted therapy could become a main strategy for the treatment of breast cancer in the near future.

참고문헌 (Reference)

1 Arpino G, "Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy" 99 : 694-705, 2007

2 Hudis CA, "Trastuzumab--mechanism of action and use in clinical practice" 357 : 39-51, 2007

3 Dancey JE, "Therapeutic targets: MTOR and related pathways" 5 : 1065-1073, 2006

4 Cantley LC, "The phosphoinositide 3-kinase pathway" 296 : 1655-1657, 2002

5 Rusnak DW, "The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo" 1 : 85-94, 2001

6 Powers MV, "Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors" 13 (13): S125-S135, 2006

7 Agus DB, "Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth" 2 : 127-137, 2002

8 Finn RS, "Targeting Src in breast cancer" 19 : 1379-1386, 2008

9 Bryant HE, "Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase" 434 : 913-917, 2005

10 Miller KD, "Randomized phase Ⅲ trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer" 23 : 792-799, 2005

11 Kong D, "Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy" 99 : 1734-1740, 2008

12 Li T, "Phase Ⅱ trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205" 20 : 642-647, 2009

13 Moreno-Aspitia A, "Phase Ⅱ trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336" 27 : 11-15, 2009

14 Finn RS, "Phase Ⅱ trial of dasatinib in triple-negative breast cancer: results of study CA180059. abstract #3118" 2008

15 Burstein HJ, "Phase Ⅱ study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane" 26 : 1810-1816, 2008

16 Baselga J, "Phase Ⅱ randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer" 27 : 2630-2637, 2009

17 Miller K, "Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer" 357 : 2666-2676, 2007

18 Curtin NJ, "PARP inhibitors for cancer therapy" 7 : 1-20, 2005

19 Baselga J, "Objective response rate in a phase Ⅱ multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. abstract #1004" 25-, 2007

20 Cantley LC, "New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway" 96 : 4240-4245, 1999

21 Burstein HJ, "Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. abstract #37" 2008

22 Serra V, "NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations" 68 : 8022-8030, 2008

23 Geyer CE, "Lapatinib plus capecitabine for HER2-positive advanced breast cancer" 355 : 2733-2743, 2006

24 Fong PC, "Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers" 361 : 123-134, 2009

25 Maira SM, "Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity" 7 : 1851-1863, 2008

26 Schubbert S, "Hyperactive Ras in developmental disorders and cancer" 7 : 295-308, 2007

27 Scaltriti M, "Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer" 99 : 628-638, 2007

28 O'Shaughnessy J, "Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. abstract #3" 27-, 2009

29 Finn RS, "Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triplenegative" breast cancer cell lines growing in vitro" 105 : 319-326, 2007

30 Modi S, "Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase Ⅰ dose-escalation study" 25 : 5410-5417, 2007

31 Johnston SR, "A phase Ⅱ, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy" 110 : 327-335, 2008

32 Vukelja S, "A phase Ⅱ study of trastuzumab-DM1, a first-in-class HER2 antibodydrug conjugate, in patients with HER2+ metastatic breast cancer. Abstract #33" 2008